CN110437145A - 酪氨酸激酶抑制剂及其应用 - Google Patents

酪氨酸激酶抑制剂及其应用 Download PDF

Info

Publication number
CN110437145A
CN110437145A CN201910822704.XA CN201910822704A CN110437145A CN 110437145 A CN110437145 A CN 110437145A CN 201910822704 A CN201910822704 A CN 201910822704A CN 110437145 A CN110437145 A CN 110437145A
Authority
CN
China
Prior art keywords
compound
cancer
washing
tyrosine kinase
organic phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910822704.XA
Other languages
English (en)
Chinese (zh)
Inventor
孙芳
占有妮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LaNova Medicines Ltd
Original Assignee
Shanghai Xiang Jin Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Xiang Jin Biotechnology Co Ltd filed Critical Shanghai Xiang Jin Biotechnology Co Ltd
Priority to CN201910822704.XA priority Critical patent/CN110437145A/zh
Publication of CN110437145A publication Critical patent/CN110437145A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201910822704.XA 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用 Pending CN110437145A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910822704.XA CN110437145A (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910822704.XA CN110437145A (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用
CN201610822529.0A CN107235896B (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201610822529.0A Division CN107235896B (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用

Publications (1)

Publication Number Publication Date
CN110437145A true CN110437145A (zh) 2019-11-12

Family

ID=59982910

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910822704.XA Pending CN110437145A (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用
CN201610822529.0A Active CN107235896B (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610822529.0A Active CN107235896B (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用

Country Status (8)

Country Link
US (1) US10882853B2 (cg-RX-API-DMAC10.html)
EP (1) EP3511327B1 (cg-RX-API-DMAC10.html)
JP (1) JP7487921B2 (cg-RX-API-DMAC10.html)
KR (2) KR20190045354A (cg-RX-API-DMAC10.html)
CN (2) CN110437145A (cg-RX-API-DMAC10.html)
AU (1) AU2017325641B2 (cg-RX-API-DMAC10.html)
ES (1) ES2902549T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018049861A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655406A1 (en) 2017-07-18 2020-05-27 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019212800B2 (en) 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
CN112358469A (zh) * 2020-03-18 2021-02-12 北京康辰药业股份有限公司 血管生成抑制剂、其制备方法及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
CN105001168A (zh) * 2015-08-25 2015-10-28 佛山市赛维斯医药科技有限公司 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途
CN105017163A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
CN105085416A (zh) * 2015-08-25 2015-11-25 佛山市赛维斯医药科技有限公司 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN105218445A (zh) * 2015-08-25 2016-01-06 江苏中邦制药有限公司 一种络氨酸酶抑制剂Foretinib的制备方法
CN105884695A (zh) * 2015-02-13 2016-08-24 山东轩竹医药科技有限公司 杂环衍生物类酪氨酸激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
CN105884695A (zh) * 2015-02-13 2016-08-24 山东轩竹医药科技有限公司 杂环衍生物类酪氨酸激酶抑制剂
CN105001168A (zh) * 2015-08-25 2015-10-28 佛山市赛维斯医药科技有限公司 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途
CN105017163A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
CN105085416A (zh) * 2015-08-25 2015-11-25 佛山市赛维斯医药科技有限公司 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN105218445A (zh) * 2015-08-25 2016-01-06 江苏中邦制药有限公司 一种络氨酸酶抑制剂Foretinib的制备方法

Also Published As

Publication number Publication date
KR102382039B1 (ko) 2022-04-01
US10882853B2 (en) 2021-01-05
ES2902549T3 (es) 2022-03-28
EP3511327A4 (en) 2019-08-07
EP3511327B1 (en) 2021-10-27
WO2018049861A1 (zh) 2018-03-22
EP3511327A1 (en) 2019-07-17
KR20190045354A (ko) 2019-05-02
CN107235896B (zh) 2019-11-05
US20190248772A1 (en) 2019-08-15
JP7487921B2 (ja) 2024-05-21
CN107235896A (zh) 2017-10-10
AU2017325641A1 (en) 2019-04-11
AU2017325641B2 (en) 2021-08-26
KR20210143935A (ko) 2021-11-29
JP2019529435A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
CN107235896B (zh) 酪氨酸激酶抑制剂及其应用
CN105263326B (zh) 甲基/氟-吡啶基-甲氧基取代的吡啶酮-吡啶基化合物及氟-嘧啶基-甲氧基取代的吡啶酮-吡啶基化合物
KR102698366B1 (ko) 피라졸 피리미딘 유도체 및 이의 용도
CN106536503B (zh) 一种酪氨酸激酶抑制剂及其用途
CN108976172B (zh) 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
KR20210065097A (ko) 치환된 인돌 및 이의 사용 방법
KR20230065261A (ko) 자가면역질환 및 암 치료용 저분자 화합물
JP2022504541A (ja) 低分子mdm2タンパク質デグレーダー
WO2012041524A1 (en) Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
Zhang et al. Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents
CN109776607B (zh) 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
WO2019024876A1 (zh) 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
CN110577546B (zh) Vegfr抑制剂及其制备方法和应用
CN113387957A (zh) 螺环吲哚酮-吡咯烷碳酸酯化合物和其组合物、制备方法及用途
TWI546304B (zh) Protein tyrosine kinase inhibitors and their use
CN108794398B (zh) 具有荧光的选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN107235897B (zh) 酪氨酸激酶抑制剂及其应用
WO2023168740A1 (zh) 喹啉类化合物的新用途
CN118724825B (zh) 一种Mer/HDAC双靶点抑制剂及其在制备抗肿瘤药物中的应用
CN118515623B (zh) 一种取代苯并异恶唑类化合物及其在制备抗肿瘤药物中的应用
CN117466889B (zh) 一种1H-吡咯[2,3-b]吡啶化合物及其合成方法和应用
JP6541635B2 (ja) Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
EA049962B1 (ru) Новые соединения, применяемые в качестве ингибиторов поли(адф-рибоза)полимеразы (parp)
CN104311494A (zh) 间-(4-吗啉基-2-喹唑啉基)苯甲酰胺类化合物及其合成方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200430

Address after: 200082 floor 3, building 1, No. 400, Fangchun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant after: Lixin Pharmaceutical Technology (Shanghai) Co.,Ltd.

Address before: 201913 room 543, building a, 2528 Panyuan Road, Changxing Town, Chongming County, Chongming District, Shanghai

Applicant before: Shanghai Xiangjin Biotechnology Co.,Ltd.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191112

WD01 Invention patent application deemed withdrawn after publication